Skip to content

Grifols SA

GRFS· NasdaqCore metricsCIK 1438569

Pharmaceutical preparations551 peers

Last sale
Nov 6, 2026 · -0.47%
Market cap
—
no share count on file
Filings
463
€7.21B
FY 2024+9.4% FY24 yoy
€156.92M
FY 2024+270.8% FY24 yoy
€1.19B
FY 2024+52.4% FY24 yoy
€669.63M
FY 2024derivedN/M FY24 yoy
€0.23
FY 2024+283.3% FY24 yoy
€979.78M
FY 2024+85.0% FY24 yoy

Price

$8.442.26%$0.20past year
Nov 6, 2026 · IEX last sale
Range
IEX last saleClose of recordAs traded

Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.

Financials

Revenue

€7.21BFY 2024
€7.21B0FY 2015FY 2016FY 2017FY 2018FY 2019FY 2020FY 2021FY 2022FY 2023FY 2024
PeriodEndedValueKindSource trail
FY 20242024-12-31€7,212,382,000reported
FY 20232023-12-31€6,591,977,000reported
FY 20222022-12-31€6,063,967,000reported
FY 20212021-12-31€4,933,118,000reported
FY 20202020-12-31€5,340,038,000reported
FY 20192019-12-31€5,098,691,000reported
FY 20182018-12-31€4,486,724,000reported
FY 20172017-12-31€4,318,073,000reported
FY 20162016-12-31€4,049,830,000reported
FY 20152015-12-31€3,934,563,000reported

Capital returns

Dividends and buybacks · FY2015 to FY2024
Fiscal yearDividendsBuybacksTotalPer shareSharesShares · yoyof free cash flow
FY2024€962.00K—€962.00K———0.1%
FY2023€0.00€0.00€0.00————
FY2022€592.00K€3.46M€4.05M————
FY2021€258.95M€125.70M€384.65M———110.0%
FY2020€113.23M—€113.23M———13.6%

Segments

Revenue by Segments, FY2023 to FY2025FY2023Biopharma · FY2023 · €5.56BDiagnostic · FY2023 · €670.00MAll Other Segments · FY2023 · €204.00MBio Supplies · FY2023 · €160.00MFY2024Biopharma · FY2024 · €6.14BDiagnostic · FY2024 · €645.00MAll Other Segments · FY2024 · €208.00MBio Supplies · FY2024 · €216.00MFY2025Biopharma · FY2025 · €6.49BDiagnostic · FY2025 · €640.00MAll Other Segments · FY2025 · €243.00MBio Supplies · FY2025 · €154.00M
LineFY2025ShareChange
Biopharma€6.49B86%+5.6%
Diagnostic€640.00M8.5%−0.8%
All Other Segments€243.00M3.2%+16.8%
Bio Supplies€154.00M2.0%−28.7%
Total€7.52B

From the 20-F filed Apr 17, 2026GRFS

Pharmaceutical preparations

552 covered companies are filed under this code. SIC 2834

Peers are the covered companies filed under the same SIC code, then under codes that share its first three digits or its first two, largest by revenue first. Figures are each company’s latest fiscal year as filed; market cap is at its latest price.

Grifols SA · CIK 1438569 · Engraved from SEC EDGAR